SCHEMBL828359

SCHEMBL828359

O=C(O)NC(Cc1ccccc1)C(OC(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 1/20 0.43
CYP19A1 P11511 1/20 0.43
CYP2D6 P10635 1/20 0.43
BACE1 P56817 2/20 0.41
SLC6A11 P48066 1/20 0.41
TP53 P04637 1/20 0.41
TSHR P16473 1/20 0.41
MDM2 Q00987 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CTRB1 P17538 3/20 0.40
ALDH1A1 P00352 1/20 0.40
HTT P42858 1/20 0.40
NCOA1 Q15788 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NCOA3 Q9Y6Q9 1/20 0.40
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27093069 0.76 TP53 (0.52) CYP2D6TP53TSHRMDM2SLC6A2
SCHEMBL828896 0.75 MDM2 (0.51) BACE1SLC6A11MDM2TDP1CTRB1
SCHEMBL4728419 0.72 NPC1 (0.50) BACE1SLC6A11MDM2CTRB1
SCHEMBL10392447 0.72 TSHR (0.55) CYP2D6TP53TSHRMDM2SLC6A2
SCHEMBL5409637 0.71 TSHR (0.53) CYP1A1CYP19A1TP53TSHRSLC6A3
SCHEMBL8078600 0.71 NPC1 (0.55) CYP1A1CYP19A1CYP2D6TP53TSHR
SCHEMBL1082231 0.71 TSHR (0.53) CYP1A1CYP19A1CYP2D6TP53TSHR
SCHEMBL5409634 0.71 TSHR (0.53) CYP1A1CYP19A1TP53TSHRSLC6A3
SCHEMBL16366772 0.71 CYP2D6 (0.54) CYP2D6TP53TSHRMDM2SLC6A2
SCHEMBL9012913 0.71 BACE1 (0.50) BACE1SLC6A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143437-B2 Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof XENOPORT, INC. (US) 2012-03-27 US disclosed
US-7560483-B2 Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof XENOPORT, INC. (US) 2009-07-14 US disclosed
US-20050239725-A1 Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof XENOPORT, INC. 2005-10-27 US disclosed
US-6927036-B2 Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof XERO PORT, INC. (US) 2005-08-09 US disclosed
EP-1485082-A1 METHODS FOR SYNTHESIS OF PRODRUGS FROM 1-ACYL-ALKYL DERIVATIVES AND COMPOSITIONS THEREOF Xenoport, Inc. (US) 2004-12-15 EP disclosed
WO-2003077902-A1 METHODS FOR SYNTHESIS OF PRODRUGS FROM 1-ACYL-ALKYL DERIVATIVES AND COMPOSITIONS THEREOF XENOPORT, INC. (US) 2003-09-25 WO disclosed
US-20030171303-A1 Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof ARBOR PHARMACEUTICALS, LLC 2003-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171303-A1 Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof AADAC, UGT1A1, AGPAT5 CYP1A1 13/4885CYP19A1 60/4885CYP2D6 25/4885
US-20050239725-A1 Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof AADAC, UGT1A1, ABHD5 CYP1A1 8/4885CYP19A1 61/4885CYP2D6 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.